<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Research Services</title>
	<atom:link href="http://www.stockbloghub.com/category/research-services/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SNMX) Senomyx Leads ValuEngine.com Forecast Screen</title>
		<link>http://www.stockbloghub.com/2011/04/07/senomyx-leads-valuengine-com-forecast-screen/70944</link>
		<comments>http://www.stockbloghub.com/2011/04/07/senomyx-leads-valuengine-com-forecast-screen/70944#comments</comments>
		<pubDate>Thu, 07 Apr 2011 18:54:47 +0000</pubDate>
		<dc:creator>valuengine</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Senomyx Inc]]></category>
		<category><![CDATA[SNMX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70944</guid>
		<description><![CDATA[Flavoring manufacturer Senomyx uses proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas. Senomyx has entered into flavoring manufacturer product discovery and development collaborations with seven of the world&#8217;s leading food, beverage, and ingredient supply companies: Ajinomoto Co., Inc., Cadbury plc, Campbell Soup Company, The Coca-Cola Company, Firmenich SA, Nestle SA, and Solae. Nestle is currently marketing products that contain one of Senomyx&#8217;s flavor ingredients. A screen for undervalued/top-ranked one-month forecast stocks with market prices in excess of $3.00 and average volume in excess of 100k shares/day performed with our Institutional software package (VEI) found Senomyx near the top of the list. ValuEngine has issued a STRONG BUY recommendation for Senomyx on Apr. 07, 2011. Based on the information ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/senomyx-leads-valuengine-com-forecast-screen/70944/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CVD) Big Pharmaceutical Companies Outsourcing Research and Development</title>
		<link>http://www.stockbloghub.com/2010/10/17/cvd-big-pharmaceutical-companies-outsourcing-research-and-development/55233</link>
		<comments>http://www.stockbloghub.com/2010/10/17/cvd-big-pharmaceutical-companies-outsourcing-research-and-development/55233#comments</comments>
		<pubDate>Mon, 18 Oct 2010 03:42:59 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55233</guid>
		<description><![CDATA[by Tony D’Altorio, Investment U Research Thursday, October 14, 2010 Big pharmaceutical companies seem to be taking tips from an unlikely source these days. A decade ago, big mining companies had a big problem on their hands in the form of declining prices. With less incoming funds to spend on finding new deposits, they started thinking creatively… They let small entrepreneurial companies handle early-stage exploration, a difficult task in remote parts of the world. Then, if those operations struck it rich, the big miners swooped in to buy them out. Drug development might not seem like it has much in common with such ventures. But it involves the same high-risk, high reward discovery efforts. So the pharmaceuticals are going for the gold as well with this new approach. Cutting back ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/17/cvd-big-pharmaceutical-companies-outsourcing-research-and-development/55233/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe Files Pre-market Approval Application for Prostate Cancer Test</title>
		<link>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758</link>
		<comments>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758#comments</comments>
		<pubDate>Mon, 27 Sep 2010 05:04:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NAT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52758</guid>
		<description><![CDATA[Diagnostic products maker Gen-Probe Inc. (GPRO) has submitted a Pre-market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer. Gen-Probe is seeking FDA approval to use the assay to test urine specimens from men who earlier had a negative prostate biopsy. This represents the second of the four PMA submissions that Gen-Probe plans to complete in 2010. The FDA has formally accepted the PROGENSA PMA and has advised Gen-Probe that a meeting (timeline unspecified) of the Medical Devices Advisory Committee&#8217;s Immunology Panel will be necessary to support approval of the filling. Gen-Probe acquired the exclusive global rights to the PCA3 (a genetic marker for prostate cancer) from Canadian cancer diagnostic tests ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe&#8217;s Earnings Report Leaps Ahead of Forecast</title>
		<link>http://www.stockbloghub.com/2010/07/31/gpro-gen-probes-earnings-report-leaps-ahead-of-forecast/45488</link>
		<comments>http://www.stockbloghub.com/2010/07/31/gpro-gen-probes-earnings-report-leaps-ahead-of-forecast/45488#comments</comments>
		<pubDate>Sat, 31 Jul 2010 16:17:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NAT]]></category>
		<category><![CDATA[Nordic American Tanker Shipping Limited]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45488</guid>
		<description><![CDATA[Diagnostic product maker Gen-Probe Inc. (GPRO) announced second-quarter fiscal 2010 adjusted earnings of 52 cents per share, exceeding the Zacks Consensus Estimate of 49 cents and the year-ago earnings of 45 cents. Net income soared 42% year-over-year to $28.1 million (or 57 cents a share), riding on solid top-line growth. Revenues Revenues surged 15% year over year to $138.6 million, beating the Zacks Consensus Estimate of $137 million, buoyed by double-digit sales growth from the clinical diagnostics and blood screening product businesses. Clinical diagnostic revenues grew 10%, fueled by higher adoption of APTIMA Combo 2 assay and Prodesse products. Blood screening product sales cruised 22% year over year to $55.7 million. Growth was supported by higher shipment of Procleix Ultrio and West Nile virus assays, as well as favorable currency ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/31/gpro-gen-probes-earnings-report-leaps-ahead-of-forecast/45488/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe Invests $50 Million in Pacific Biosciences</title>
		<link>http://www.stockbloghub.com/2010/07/05/gpro-gen-probe-invests-50-million-in-pacific-biosciences/40813</link>
		<comments>http://www.stockbloghub.com/2010/07/05/gpro-gen-probe-invests-50-million-in-pacific-biosciences/40813#comments</comments>
		<pubDate>Mon, 05 Jul 2010 16:14:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NAT]]></category>
		<category><![CDATA[Nordic American Tanker Shipping Limited]]></category>
		<category><![CDATA[SMRT]]></category>
		<category><![CDATA[Stein Mart Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=40813</guid>
		<description><![CDATA[Diagnostic product maker Gen-Probe Inc (GPRO) has made a $50 million strategic investment in privately-held DNA sequencing firm Pacific Biosciences (PacBio). The companies will collaborate on developing products based on their proprietary technologies. Per the deal, the companies will combine their efforts to develop new clinical diagnostic systems, leveraging PacBio&#8217;s Single Molecule Real Time (SMRT) DNA sequencing technology platform and Gen-Probe&#8217;s diagnostic expertise. They will initially collaborate for up to 30 months with the goal of building a long-term relationship and improving diagnostic capabilities. Moreover, the companies will buy each other&#8217;s products on preferred terms of trade. California-based Gen-Probe has been a pioneer in the commercial and scientific development of nucleic acid testing (NAT) for the diagnosis of infectious diseases. The company sells its products in the clinical diagnostic as well ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/05/gpro-gen-probe-invests-50-million-in-pacific-biosciences/40813/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GTF) Cytomedix Analyst Awards Outperform Rating</title>
		<link>http://www.stockbloghub.com/2010/04/19/gtf-cytomedix-analyst-awards-outperform-rating/34315</link>
		<comments>http://www.stockbloghub.com/2010/04/19/gtf-cytomedix-analyst-awards-outperform-rating/34315#comments</comments>
		<pubDate>Mon, 19 Apr 2010 21:46:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Cytomedix Inc]]></category>
		<category><![CDATA[GTF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34315</guid>
		<description><![CDATA[We are initiating coverage of Cytomedix (GTF) with an ‘Outperform’ rating and near-term price target of $1.50 per share. At this price, we do not believe the market has come to grips with the transformation underway at Cytomedix, thanks to the recent acquisition of the Angel Whole Blood Separation System and ActivAT Autologous Thrombin Processing Kit from the Sorin Group completed on April 9, 2010. Management acquired these two key assets for a price of $7 million in cash, with $2.0 million upfront and $5.0 million in the form of a promissory note payable in installments over the next 2.5 years. The Angel whole blood separation device reported sales in 2009 of approximately $4.8 million, up 7% from 2008, and generated profits of approximately $1.7 million. Cytomedix exited 2009 with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/19/gtf-cytomedix-analyst-awards-outperform-rating/34315/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OXBT) Oxygen Biotherapeutics Moves Into New Business</title>
		<link>http://www.stockbloghub.com/2010/03/30/oxbt-oxygen-biotherapeutics-moves-into-new-business/32278</link>
		<comments>http://www.stockbloghub.com/2010/03/30/oxbt-oxygen-biotherapeutics-moves-into-new-business/32278#comments</comments>
		<pubDate>Tue, 30 Mar 2010 14:33:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[OXBT]]></category>
		<category><![CDATA[Oxygen Biotherapeutics]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32278</guid>
		<description><![CDATA[This morning, Oxygen Biotherapeutics (OXBT) announced that the company has begun distribution for its new formulation of Dermacyte (perfluorocarbon oxygen concentrated gel) for the beauty and skin care market. This is essentially the full-scale rollout of Dermacyte following the pilot launch in the fourth quarter 2009 when the company made available 5,000 boxes on the company’s website, www.BuyDermacyte.com. According to management, the product sold out in the first month after the initial stock became available online. The new formulation, which will be manufactured in continuing batches Incorporatedorporates a smoother and more effective concentrate to provide oxygen to the skin. The product helps promote the healthy appearance of skin by minimizing the appearance of fine lines, brightening and smoothing the complexion, and by keeping skin moist and oxygenated. Currently marketed as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/30/oxbt-oxygen-biotherapeutics-moves-into-new-business/32278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) IMS Health Reports Earnings In Line</title>
		<link>http://www.stockbloghub.com/2010/02/10/rx-ims-health-reports-earnings-in-line/27662</link>
		<comments>http://www.stockbloghub.com/2010/02/10/rx-ims-health-reports-earnings-in-line/27662#comments</comments>
		<pubDate>Thu, 11 Feb 2010 00:17:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[RX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27662</guid>
		<description><![CDATA[IMS Health (RX) reported fourth-quarter earnings per share (EPS) of 39 cents, in line with the Zacks Consensus Estimate. However, after adjusting for charges related to restructuring initiatives, asset impairment and others, EPS came in at 52 cents compared to 50 cents in the year-ago period. For the full year of 2009, IMS reported an EPS of $1.73 after adjustments compared to $1.70 in 2008. Revenues during the reported quarter came in at $599.2 million, an increase of 3% compared to the corresponding period last year. This is an improvement from the third quarter when curtailed spending by clients due to the economic downturn brought down revenues by 6%. For 2009, revenues came in at $2.18 billion, down 6% compared to $2.32 billion in 2008. IMS categorizes its revenue under ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/10/rx-ims-health-reports-earnings-in-line/27662/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Pharma &amp; Biotech Stock Review &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385</link>
		<comments>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26385</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe Earns U.S. Food and Drug Administration Approval</title>
		<link>http://www.stockbloghub.com/2009/11/25/gpro-gen-probe-earns-u-s-food-and-drug-administration-approval/21307</link>
		<comments>http://www.stockbloghub.com/2009/11/25/gpro-gen-probe-earns-u-s-food-and-drug-administration-approval/21307#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:14:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21307</guid>
		<description><![CDATA[Recently, Gen-Probe Inc. (GPRO) announced that it has received the green light from the U.S. Food and Drug Administration (FDA) to market ProParaflu Plus assay. The assay, developed by Prodesse, a wholly-owned subsidiary of Gen-Probe, is a molecular test for detecting and differentiating parainfluenza 1, 2, and 3 viruses that cause lower respiratory tract infections. The assay makes use of real-time polymerase chain reaction to identify parainfluenza 1, 2, and 3 viruses from nasal swabs. Since it utilizes the same internal control as Prodesse&#8217;s other tests for respiratory infectious diseases, a single nucleic acid extract can be tested with any combination of its other products which have received FDA clearance &#8211; ProFlu Plus, Pro hMPV Plus and ProFlu-ST. As a reminder, ProFlu Plus received FDA approval in 2008 for detecting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/gpro-gen-probe-earns-u-s-food-and-drug-administration-approval/21307/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) IMS Health to be Acquired by Funds Managed by TPG Capital</title>
		<link>http://www.stockbloghub.com/2009/11/14/rx-ims-health-to-be-acquired-by-funds-managed-by-tpg-capital/20537</link>
		<comments>http://www.stockbloghub.com/2009/11/14/rx-ims-health-to-be-acquired-by-funds-managed-by-tpg-capital/20537#comments</comments>
		<pubDate>Sat, 14 Nov 2009 23:42:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[RX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20537</guid>
		<description><![CDATA[IMS Health (RX) recently agreed to its acquisition by investment funds managed by TPG Capital (TPG) and the Canada Pension Plan Investment Board (CPPIB) for a total value of $5.2 billion. The Board of Directors approved the decision based on the Transaction Committee recommendation, which was set up to review IMS’ strategic alternatives. Following the agreement, IMS shareholders will receive $22 cash for each share of IMS stock they own. The transaction is likely to be completed by the first quarter of 2010. The transaction will be financed by a combination of equity to be invested by TPG and CPPIB and debt financing to be provided by Goldman Sachs &#38; Co. Incorporatedluding its principal loan and mezzanine funds. Earlier, in October, IMS announced that it is exploring several strategic alternatives. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/rx-ims-health-to-be-acquired-by-funds-managed-by-tpg-capital/20537/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Big Pharma and Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146</link>
		<comments>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:57:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) IMS Health Earnings Ahead of Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/22/rx-ims-health-earnings-ahead-of-consensus-estimates/18548</link>
		<comments>http://www.stockbloghub.com/2009/10/22/rx-ims-health-earnings-ahead-of-consensus-estimates/18548#comments</comments>
		<pubDate>Thu, 22 Oct 2009 22:43:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[RX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18548</guid>
		<description><![CDATA[This morning, IMS Health (RX) reported third-quarter earnings per share of 40 cents, beating the Zacks Consensus Estimate by 4 cents. However, earnings declined 7% from the year-ago period. Revenues came in at $540.8 million. With clients reining in their spending due to the economic downturn, revenues declined 6%. Curtailed spending should continue affecting revenues. Operating income for the quarter was $100.8 million, down 21% from the year-ago period. The company did not undertake any share repurchasing activities during the quarter even though 9.5 million shares remain authorized and available for repurchase. Preliminary free cash flow was $155.2 million. The company exited the quarter with $301.7 million in cash and cash equivalents. Total debt declined to $1,344.9 million, compared to $1,404.2 million at the end of 2008. The company reported ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/22/rx-ims-health-earnings-ahead-of-consensus-estimates/18548/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRXL) PAREXEL International Corporation &#8211; Value &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/02/prxl-parexel-international-corporation-value-zacks-rank-buy/5021</link>
		<comments>http://www.stockbloghub.com/2009/04/02/prxl-parexel-international-corporation-value-zacks-rank-buy/5021#comments</comments>
		<pubDate>Thu, 02 Apr 2009 19:25:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Parexel International Corp.]]></category>
		<category><![CDATA[PRXL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5021</guid>
		<description><![CDATA[PAREXEL International Corporation (PRXL), which provides consulting services to the drug and medical device industries, reported record service revenue that climbed 15.6% in its fiscal second quarter. The company has surprised on estimates 4 consecutive quarters by an average of 9.08%. PRXL has a PEG ratio of 0.60. Company Description PAREXEL International provides contract research and consulting services to the pharmaceutical, biotech and medical device industries in 51 countries around the world. The company&#8217;s services include helping clients bring new drugs to market through all phases of drug development and commercialization Incorporatedluding regulatory consulting and clinical trials. Service Revenue Hits Record in the Second Quarter 2009 PAREXEL reported second quarter fiscal 2009 results on Jan 26 and beat Wall Street estimates by 15%. Excluding a charge for a contract termination ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/02/prxl-parexel-international-corporation-value-zacks-rank-buy/5021/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMRI) &#8211; Albany Molecular Research &#8211; earnings of 24 cents per share, far ahead of analyst estimates of 10 cents</title>
		<link>http://www.stockbloghub.com/2008/10/09/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-4/880</link>
		<comments>http://www.stockbloghub.com/2008/10/09/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-4/880#comments</comments>
		<pubDate>Thu, 09 Oct 2008 13:00:51 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMRI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001880/2008/10/09/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-4</guid>
		<description><![CDATA[Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.Company Description Albany Molecular Research provides contract services to pharmaceutical and biotechnology companies in the U.S. and internationally. The company was founded in 1991, has a market cap of $576 million and is headquartered in Albany, New York. Albany is one of the few company&#8217;s that has performed well in the choppy market over the last few weeks, with its share price actually hitting a new 52-week high. This strength is a product of Albany&#8217;s fundamental profile, on full display when the company reported excellent second-quarter results on Aug 6. Second-Quarter Results Revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/09/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-4/880/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMRI) &#8211; Albany Molecular Research &#8211; earnings of 24 cents per share, far ahead of analyst estimates of 10 cents</title>
		<link>http://www.stockbloghub.com/2008/10/07/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-3/820</link>
		<comments>http://www.stockbloghub.com/2008/10/07/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-3/820#comments</comments>
		<pubDate>Tue, 07 Oct 2008 13:21:41 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMRI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001820/2008/10/07/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-3</guid>
		<description><![CDATA[Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.Company Description Albany Molecular Research provides contract services to pharmaceutical and biotechnology companies in the U.S. and internationally. The company was founded in 1991, has a market cap of $576 million and is headquartered in Albany, New York. Albany is one of the few company&#8217;s that has performed well in the choppy market over the last few weeks, with its share price actually hitting a new 52-week high. This strength is a product of Albany&#8217;s fundamental profile, on full display when the company reported excellent second-quarter results on Aug 6. Second-Quarter Results Revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/07/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-3/820/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMRI) &#8211; Albany Molecular Research &#8211; earnings of 24 cents per share, far ahead of analyst estimates of 10 cents</title>
		<link>http://www.stockbloghub.com/2008/10/02/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-2/775</link>
		<comments>http://www.stockbloghub.com/2008/10/02/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-2/775#comments</comments>
		<pubDate>Thu, 02 Oct 2008 16:20:11 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMRI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001775/2008/10/02/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-2</guid>
		<description><![CDATA[Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.Company Description Albany Molecular Research provides contract services to pharmaceutical and biotechnology companies in the U.S. and internationally. The company was founded in 1991, has a market cap of $576 million and is headquartered in Albany, New York. Albany is one of the few company&#8217;s that has performed well in the choppy market over the last few weeks, with its share price actually hitting a new 52-week high. This strength is a product of Albany&#8217;s fundamental profile, on full display when the company reported excellent second-quarter results on Aug 6. Second-Quarter Results Revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/02/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents-2/775/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMRI) &#8211; Albany Molecular Research &#8211; earnings of 24 cents per share, far ahead of analyst estimates of 10 cents</title>
		<link>http://www.stockbloghub.com/2008/10/01/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents/742</link>
		<comments>http://www.stockbloghub.com/2008/10/01/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents/742#comments</comments>
		<pubDate>Thu, 02 Oct 2008 03:20:10 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMRI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001742/2008/10/01/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents</guid>
		<description><![CDATA[Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.Company Description Albany Molecular Research provides contract services to pharmaceutical and biotechnology companies in the U.S. and internationally. The company was founded in 1991, has a market cap of $576 million and is headquartered in Albany, New York. Albany is one of the few company&#8217;s that has performed well in the choppy market over the last few weeks, with its share price actually hitting a new 52-week high. This strength is a product of Albany&#8217;s fundamental profile, on full display when the company reported excellent second-quarter results on Aug 6. Second-Quarter Results Revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/01/amri-albany-molecular-research-earnings-of-24-cents-per-share-far-ahead-of-analyst-estimates-of-10-cents/742/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMRI) &#8211; Albany Molecular Research &#8211; A 140% Earnings Surprise</title>
		<link>http://www.stockbloghub.com/2008/09/19/amri-albany-molecular-research-a-140-earnings-surprise-4/604</link>
		<comments>http://www.stockbloghub.com/2008/09/19/amri-albany-molecular-research-a-140-earnings-surprise-4/604#comments</comments>
		<pubDate>Fri, 19 Sep 2008 12:00:09 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMRI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001604/2008/09/19/amri-albany-molecular-research-a-140-earnings-surprise-4</guid>
		<description><![CDATA[Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.Company Description Albany Molecular Research, Inc. provides an extensive list of research and development services for pharmaceutical companies, such as drug development and chemistry research in addition to some small-scale production. The company was founded in Albany, New York, has approximately 1,200 employees, and carries a market cap of $575 million. A 140% Earnings Surprise On August 6th Albany Molecular reported second-quarter earnings of $5.7 million which. After adjusting for a restructuring charge, that translates to 24 cents per share. The consensus estimate was only 10 cents per share, yielding a 140% earnings ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/09/19/amri-albany-molecular-research-a-140-earnings-surprise-4/604/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMRI) &#8211; Albany Molecular Research &#8211; A 140% Earnings Surprise</title>
		<link>http://www.stockbloghub.com/2008/09/17/amri-albany-molecular-research-a-140-earnings-surprise-3/570</link>
		<comments>http://www.stockbloghub.com/2008/09/17/amri-albany-molecular-research-a-140-earnings-surprise-3/570#comments</comments>
		<pubDate>Wed, 17 Sep 2008 12:20:15 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMRI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001570/2008/09/17/amri-albany-molecular-research-a-140-earnings-surprise-3</guid>
		<description><![CDATA[Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.Company Description Albany Molecular Research, Inc. provides an extensive list of research and development services for pharmaceutical companies, such as drug development and chemistry research in addition to some small-scale production. The company was founded in Albany, New York, has approximately 1,200 employees, and carries a market cap of $575 million. A 140% Earnings Surprise On August 6th Albany Molecular reported second-quarter earnings of $5.7 million which. After adjusting for a restructuring charge, that translates to 24 cents per share. The consensus estimate was only 10 cents per share, yielding a 140% earnings ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/09/17/amri-albany-molecular-research-a-140-earnings-surprise-3/570/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMRI) &#8211; Albany Molecular Research &#8211; A 140% Earnings Surprise</title>
		<link>http://www.stockbloghub.com/2008/09/10/amri-albany-molecular-research-a-140-earnings-surprise-2/528</link>
		<comments>http://www.stockbloghub.com/2008/09/10/amri-albany-molecular-research-a-140-earnings-surprise-2/528#comments</comments>
		<pubDate>Wed, 10 Sep 2008 11:21:05 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMRI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001528/2008/09/10/amri-albany-molecular-research-a-140-earnings-surprise-2</guid>
		<description><![CDATA[Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.Company Description Albany Molecular Research, Inc. provides an extensive list of research and development services for pharmaceutical companies, such as drug development and chemistry research in addition to some small-scale production. The company was founded in Albany, New York, has approximately 1,200 employees, and carries a market cap of $575 million. A 140% Earnings Surprise On August 6th Albany Molecular reported second-quarter earnings of $5.7 million which. After adjusting for a restructuring charge, that translates to 24 cents per share. The consensus estimate was only 10 cents per share, yielding a 140% earnings ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/09/10/amri-albany-molecular-research-a-140-earnings-surprise-2/528/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMRI) &#8211; Albany Molecular Research &#8211; A 140% Earnings Surprise</title>
		<link>http://www.stockbloghub.com/2008/09/05/amri-albany-molecular-research-a-140-earnings-surprise/464</link>
		<comments>http://www.stockbloghub.com/2008/09/05/amri-albany-molecular-research-a-140-earnings-surprise/464#comments</comments>
		<pubDate>Sat, 06 Sep 2008 01:40:11 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMRI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001464/2008/09/05/amri-albany-molecular-research-a-140-earnings-surprise</guid>
		<description><![CDATA[Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.Company Description Albany Molecular Research, Inc. provides an extensive list of research and development services for pharmaceutical companies, such as drug development and chemistry research in addition to some small-scale production. The company was founded in Albany, New York, has approximately 1,200 employees, and carries a market cap of $575 million. A 140% Earnings Surprise On August 6th Albany Molecular reported second-quarter earnings of $5.7 million which. After adjusting for a restructuring charge, that translates to 24 cents per share. The consensus estimate was only 10 cents per share, yielding a 140% earnings ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/09/05/amri-albany-molecular-research-a-140-earnings-surprise/464/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ICLR) &#8211; ICON Plc &#8211; Analysts project an earnings growth rate of 32%</title>
		<link>http://www.stockbloghub.com/2008/09/04/iclr-icon-plc-analysts-project-an-earnings-growth-rate-of-32-2/432</link>
		<comments>http://www.stockbloghub.com/2008/09/04/iclr-icon-plc-analysts-project-an-earnings-growth-rate-of-32-2/432#comments</comments>
		<pubDate>Thu, 04 Sep 2008 15:00:12 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[PRO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001432/2008/09/04/iclr-icon-plc-analysts-project-an-earnings-growth-rate-of-32-2</guid>
		<description><![CDATA[ICON Plc (ICLR) made several key acquisitions and partnerships this year and continues to expand globally. The company also just announced great second-quarter results for its fourth earnings surprise in as many quarters.Company Description ICON Plc. provides outsource services for pharmaceutical and biotech companies. The company specializes in development, management, and analysis of programs supporting clinical trials. ICON helps its clients cut costs in research and development of new drugs and medical devices. The company is headquartered in Dublin, Ireland and currently has over 6500 employees in offices across Europe, Asia, and the United States. Another Strong Quarter On July 22nd ICON announced second-quarter results that included earnings per share, before the stock split, of 62 cents, up from 45 cents in the second quarter last year. Analysts expected 59 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/09/04/iclr-icon-plc-analysts-project-an-earnings-growth-rate-of-32-2/432/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ICLR) &#8211; ICON Plc &#8211; Analysts project an earnings growth rate of 32%</title>
		<link>http://www.stockbloghub.com/2008/08/23/iclr-icon-plc-analysts-project-an-earnings-growth-rate-of-32/355</link>
		<comments>http://www.stockbloghub.com/2008/08/23/iclr-icon-plc-analysts-project-an-earnings-growth-rate-of-32/355#comments</comments>
		<pubDate>Sat, 23 Aug 2008 17:00:05 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[PRO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001355/2008/08/23/iclr-icon-plc-analysts-project-an-earnings-growth-rate-of-32</guid>
		<description><![CDATA[ICON Plc (ICLR) made several key acquisitions and partnerships this year and continues to expand globally. The company also just announced great second-quarter results for its fourth earnings surprise in as many quarters.Company Description ICON Plc. provides outsource services for pharmaceutical and biotech companies. The company specializes in development, management, and analysis of programs supporting clinical trials. ICON helps its clients cut costs in research and development of new drugs and medical devices. The company is headquartered in Dublin, Ireland and currently has over 6500 employees in offices across Europe, Asia, and the United States. Another Strong Quarter On July 22nd ICON announced second-quarter results that included earnings per share, before the stock split, of 62 cents, up from 45 cents in the second quarter last year. Analysts expected 59 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/08/23/iclr-icon-plc-analysts-project-an-earnings-growth-rate-of-32/355/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ICLR) &#8211; ICON Plc &#8211; an indication that investors are expecting strong earnings from the company</title>
		<link>http://www.stockbloghub.com/2008/08/07/iclr-icon-plc-an-indication-that-investors-are-expecting-strong-earnings-from-the-company/304</link>
		<comments>http://www.stockbloghub.com/2008/08/07/iclr-icon-plc-an-indication-that-investors-are-expecting-strong-earnings-from-the-company/304#comments</comments>
		<pubDate>Thu, 07 Aug 2008 19:40:04 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ICLR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/001304/2008/08/07/iclr-icon-plc-an-indication-that-investors-are-expecting-strong-earnings-from-the-company</guid>
		<description><![CDATA[ICON Plc&#8217;s (ICLR) share price has been steadily climbing higher for most of 2008, producing excellent returns in a very challenging environment. The company&#8217;s second-quarter results were ahead of analyst estimates for the fourth time in the last four quarters, providing additional fundamental strength to drive shares higher.ICON Plc offers clinical research services to pharmaceutical and biotechnology companies in the United States and Europe. The company was founded in 1990, has a market cap of $2.44 billion and is headquartered in Dublin, Ireland. Second-Quarter Results Shares of ICLR have extended their gains after the company reported excellent second-quarter results on July 22. Revenue was up 49% from last year to $218 million. Net income totaled $18.8 million, up from $13.3 million in the same period last year. This produced earnings ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/08/07/iclr-icon-plc-an-indication-that-investors-are-expecting-strong-earnings-from-the-company/304/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

